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Abstract Phospholipase A2 (PLA2) appears to play a funda-
mental role in cell injury in the central nervous system. We have
investigated PLA2 expression in the astrocytoma cell line
1231N1, and found that GIVA, GIVB, GIVC and GVI PLA2
messages are expressed. PLA2 activity is increased by in£am-
matory/injury stimuli such as interleukin-1L and lipopolysac-
charide in these cells but with very di¡erent time courses. The
arachidonic acid liberated is converted to prostaglandin E2,
possibly by cyclooxygenase-2, which is induced by in£ammatory
stimuli. This cell system emerges as a model to study injury/
in£ammation-related activation of the new PLA2 forms GIVB
and GIVC.
0 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Phospholipase A2 (PLA2) acts on the sn-2 position of phos-
pholipids to generate a free fatty acid and a lysophospholipid
[1]. PLA2 has been implicated in in£ammatory processes be-
cause it regulates the generation of pro-in£ammatory media-
tors (prostaglandins, leukotrienes, etc.) through cyclooxyge-
nase (COX) and lipoxygenase pathways [2]. In the last
decade a large e¡ort has been made to purify, sequence, and
characterize enzymes with PLA2 activity. To date, 14 di¡erent
groups of PLA2s have been described [3,4]. From a functional
point of view, PLA2s from mammalian sources have been
classi¢ed in secreted (groups IB, IIA, IIC, IID, IIE, IIF, III,
V, X, and XII), Ca2þ-dependent cytosolic (groups IVA, IVB
and IVC), and Ca2þ-independent cytosolic PLA2s (groups
VIA-1, VIA-2 and VIB) [3]. Of these, only a few have been
studied in su⁄cient detail to elucidate their role in arachidonic
acid (AA) release and eicosanoid production in mammalian
cells [5^7].
The role of PLA2 in the nervous system is not yet well
de¢ned, which is due, at least in part, to the complexity in
the expression of PLA2 groups in this system, to the lack of
speci¢c inhibitors for each of these PLA2 groups and to the
system itself, which presents a complex network of cellular
interrelations. Under physiological conditions, PLA2 is in-
volved in phospholipid turnover, membrane remodeling, exo-
cytosis, detoxi¢cation of phospholipid peroxides, and neuro-
transmitter release. However, under pathological situations,
increased PLA2 activity results in the loss of essential mem-
brane glycerophospholipids, resulting in altered membrane
permeability, ion homeostasis, increased free fatty acid re-
lease, and the accumulation of lipid peroxides [8]. These pro-
cesses may culminate in subsequent neuronal injury found in
ischemia and spinal cord injury, and in neurodegenerative
diseases such as Alzheimer’s disease [8]. Evidence of PLA2’s
role in brain injury comes from a murine transgenic model
carrying a targeted mutation of the GIVA PLA2 [9]. Animals
homozygous for the mutation (PLA23/3) are signi¢cantly
resistant to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-in-
duced neurotoxicity and had reduced injury after cerebral
ischemia [9,10].
2. Expression of PLA2 in the mammalian nervous system
2.1. Rodent nervous system
There is limited information about PLA2 expression in the
nervous system [2,11]. Brain PLA2 activity was identi¢ed and
characterized in the 1970s by several researchers [12^14], but
the assignment of these activities to speci¢c PLA2 groups did
not begin until the 1990s. Among these recent assignments,
Oka and Arita found the GIIA PLA2 to be induced by in-
£ammatory factors in cultured rat astrocytes [15]. Others have
studied the expression of PLA2 mRNAs in de¢ned areas of
the rat brain [11]. The GIIA, GIIC, GIVA, and GVIA PLA2
mRNAs appear to be ubiquitously expressed as shown by
PCR techniques. No trace of GIB PLA2 has been observed.
GIIA PLA2 was found at very high levels in brainstem and
midbrain. GIIC PLA2 was detected exclusively in brain with
no expression in peripheral tissues. Its expression was very
high in all brain regions except brainstem, thalamus, and cer-
ebellum, where levels were lower compared to other regions of
0014-5793 / 02 / $22.00 L 2002 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 2 ) 0 3 4 8 1 - 6
*Corresponding author. Permanent address: Instituto de Investiga-
ciones Biomedicas ‘‘Alberto Sols’’, Consejo Superior de Investiga-
ciones Cient|¤¢cas, Universidad Auto¤noma de Madrid, E-28029 Ma-
drid, Spain. Fax: (34)-91-585 45 87.
**Corresponding author. Fax: (1)-858-534 7390.
E-mail addresses: ivarela@iib.uam.es (I. Varela-Nieto),
edennis@ucsd.edu (E.A. Dennis).
1 Present address: Instituto de Biolog|¤a y Gene¤tica Molecular,
Consejo Superior de Investigaciones Cient|¤¢cas, Facultad de
Medicina, Universidad de Valladolid, E-47005 Valladolid, Spain.
2 Equal contribution to this work.
Abbreviations: AA, arachidonic acid; COX, cyclooxygenase; IL-1,
interleukin 1; LPS, lipopolysaccharide; MAFP, methyl arachidonyl-
£uorophosphonate; PGE2, prostaglandin E2 ; PLA2, phospholipase
A2 ; TNF-K, tumor necrosis factor-K
FEBS 26647 15-10-02
FEBS 26647FEBS Letters 531 (2002) 12^17
the brain [11]. In contrast, GV PLA2 mRNA was found at
low levels in most areas of the brain except the hippocampus,
where it was expressed at very high levels. The GIVA PLA2
was also expressed in all brain regions, the highest levels
found in the brainstem, hippocampus, striatum and midbrain,
and in contrast at relatively low levels in the cerebellum. Fi-
nally, GVIA PLA2 had a very high expression in all brain
regions. [11]. By measuring activity levels, we have found
that Ca2þ-independent PLA2 constitutes the dominant activity
in adult rat brain, with the highest levels located in the hippo-
campus and striatum [16]. Moreover, this activity is subject to
developmental changes, increasing during development after
birth and peaking at 12 weeks [16].
When an injury occurs in the brain, such as after transient
forebrain ischemia, a dramatic increase in expression of GIIA
PLA2 mRNA has been reported. This enhanced expression is
localized in ischemia vulnerable regions such as the hippo-
campus and neocortex [17]. GIIA PLA2 expression is en-
hanced also after endotoxic shock, giving very high level of
expression in a large number of brain regions [17]. GIVA
PLA2 expression has been studied in acute injury in the rat
nervous system. After focal or global ischemia, or facial nerve
axotomy (FNA), immuno-histochemistry for the GIVA re-
vealed staining in glial cells within the region of neuron
loss, with astrocytes being the most consistent cell type immu-
noreactive for GIVA PLA2 following injury. [18]. After ische-
mia, the staining overlapped with neurodegeneration areas,
whereas after FNA, GIVA PLA2 was observed surrounding
the axotomized motor neurons where synaptic loss was seen
[18].
In contrast to the rat brain, mouse brain expresses fewer
PLA2s. mRNA for GXII, the most recent secreted PLA2
group described, has been detected using RT-PCR [19,20]
and very recently, another secreted PLA2, GIIF, has been
found in brains of mice injected with lipopolysaccharide
(LPS) intraperitoneally, to simulate an in£ammatory reaction
[21]. On the other hand the GVI PLA2 has been shown to
immunolocalize in astrocytes from the spinal cord under
chronic injury in an amyotrophic lateral sclerosis transgenic
model where neuropathological degeneration of motor neu-
rons occurs [18].
2.2. Human nervous system
Our knowledge of PLA2s in the human nervous system is
also very limited. The ¢rst identi¢cation of a PLA2 group in
human brain was done by immuno-histochemistry studies per-
formed on brain slices [22]. It was shown that the majority of
brain GIVA PLA2 is present in astrocytes from the gray mat-
ter [22]. The two new human paralogs of GIVA PLA2, GIVB
and GIVC, are expressed in whole brain without regional
di¡erences between brain areas [23]. Other recent studies
have shown that GVIA, GVIB and GXII PLA2s are also ex-
pressed in human brain [4,24]. Under neurodegeneration con-
ditions such as Alzheimer’s disease, there is an increase in
immunoreactivity to GIV PLA2 in astrocytes from the cortex
of patients [18].
Interestingly, there are some PLA2 forms that have not
been found to date to be expressed in the mammalian nervous
system (mouse, rat or human) such as the GIID, GIIE and
GX forms [20,25,26], suggesting that each PLA2 group has a
distinct role in the di¡erent tissues.
The fact that astrocytes express PLA2 and that they are
immunoactive cells involved in defense mechanisms respond-
ing to external injury, makes them an attractive model system
to study PLA2 expression, regulation, and function in the
human brain, speci¢cally under in£ammatory/injury condi-
tions. Studies in the human astrocytoma cell line 1231N1
have shown the expression of GIV PLA2 by Western-blot
techniques and its stimulation by carbachol, thrombin, exog-
enous human PLA2, and tumor necrosis factor (TNF)-K
[27,28]. All of these stimuli promote the phosphorylation of
GIV PLA2 and release of AA to the extracellular medium
[27,28].
We have extended the studies on astrocyte PLA2s by ana-
lyzing the expression of the di¡erent PLA2 groups by RT-
PCR in the human astrocytoma cell line 1231N1. The primers
used were designed from the human gene sequences (Table 1).
As indicated in Fig. 1, GIVA PLA2, GIVB PLA2, GIVC
PLA2 and GVIA PLA2 are all present in this cell line. To
the contrary, no trace of any secreted PLA2 tested could be
detected in resting cells (GIIA, IID, GV or GX) under our
experimental conditions. The products generated in the PCR
reactions were analyzed later by sequencing to con¢rm their
identity. The presence of GIVA was further con¢rmed by
Western-blotting (see below).
Very little is known about the expression of GIVB
PLA2 and GIVC PLA2 in primary cultures and cell lines.
Recently, it has been described that GIVC PLA2 is present
Table 1
Oligonucleotide primers used for ampli¢cation of PLA2 groups from cDNA
PLA2 group Primer sequences Product (bp)
IIA PLA2 sense 5P-CTTACCATGAAGACCCTCCTACTGTTGGCA-3P 443
antisense 5P-GAGGGGACTCAGCAACGAGGGGTGCT-3P
IVA PLA2 sense 5P-GAGTTTTGGGCGTTTCTGGT-3P 450
antisense 5P-ACGGCAGGTTAAATGTGAGC-3P
IVB PLA2 sense 5P-GAGCGAGTTACGAGAATTCC-3P 420
antisense 5P-CACATGGGATTCCAGATCAG-3P
IVC PLA2 sense 5P-TACTCTCTGACCGACTTCTG-3P 287
antisense 5P-GTGAGTTCTGACCAGTCTTC-3P
V PLA2 sense 5P-CAAGGAGGCTTGCTGGACCTAA-3P 359
antisense 5P-CAGAGGATGTTGGGAAAGT-3P
VIA PLA2 sense 5P-AACGTTAACCTCAGGCCTCC-3 217
antisense 5P-GAGAGTTTCTTCACCTTGTT-3P
X PLA2 sense 5P-GGAATTCGCCTATATGAAATATGGT-3P 327
antisense 5P-GGAATTCAAGGTAGTCAGTCACACTTG-3P
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in human macrophages [29]. However, its role has not yet
been de¢ned.
The tissue-speci¢c distribution of the di¡erent PLA2 groups
suggests that the di¡erent forms may play distinct functional
roles. It is intriguing to explore the function of PLA2s, espe-
cially in the nervous system where knowledge regarding reg-
ulation both in normal and injured cells is limited. It is inter-
esting to note that the part of the nervous system that has the
widest and highest expression of PLA2 groups is the hippo-
campus [11,16]. Since the hippocampus is related to memory
and the generation of neurons, the elucidation of the role of
PLA2 in that part of the brain will be of great interest.
3. PLA2 : implication for in£ammation/injury in brain
Neuronal survival is dependent on glial function, which can
exert both neuroprotective and neurotoxic in£uences. Glial
cells (including astrocytes) are a primary target of cytokines
and are activated in response to many of them, including
TNF-K and interleukin (IL)-1 [30]. This activation can trigger
further release of cytokines that might enhance or suppress
local in£ammatory responses and neuronal survival. IL-1, the
prototypic in£ammatory cytokine, comprises a family of pro-
teins that are the products of separate genes. Brain cells can
express all members of the IL-1 family, albeit at low levels, in
the healthy nervous system [31]. Following experimental in-
jury, infection or in£ammation, microglia (brain macro-
phages) appear to be the early primary source of IL-1 [32].
Astrocytes also produce IL-1, usually slightly later than mi-
croglia after an acute insult [32]. It remains unclear whether
endogenous IL-1 plays a physiological role in normal, healthy
brain, since its expression is barely detectable. There is evi-
dence suggesting that endogenous IL-1 in£uences sleep pat-
terns and synaptic plasticity [31], but the majority of the ac-
tions of exogenous and endogenous IL-1 are associated with
responses to local or systemic insult. IL-1 is also believed to
act as a mediator of neuroimmune responses to disease and
neurodegeneration [32].
TNF-K has a more con£icting role than IL-1 in the nervous
system, because it can enhance and inhibit neuronal injury,
depending on the time-course and level of expression [11].
TNF-K is a 17 kDa protein with both secretory and mem-
brane-bound forms, the active form usually found as a homo-
trimer [33]. Neurons appear to be the principal cell type pro-
ducing TNF-K under physiological conditions. TNF-K
interacts with multiple neurotransmitters, and participates in
synaptic activity. In addition to its e¡ects as an endogenous
pyrogen on hypothalamic neurons, TNF-K may modulate the
Fig. 1. PCR ampli¢cation of PLA2 groups present in 1231N1 cells.
cDNA from resting cells was ampli¢ed by PCR with Taq polymer-
ase using the primers listed in Table 1: GIVA (lanes 1 and 2),
GIVB (lanes 3 and 4), GIVC (lanes 5 and 6) and GVIA PLA2
(lanes 7 and 8). Control reactions were run without DNA (lanes 2,
4, 6 and 7). RNA was extracted by the TRIZOL reagent method
(Life Technologies), as indicated by the manufacturer and reverse
transcription of the ¢rst strand cDNA was performed with total
RNA (2 Wg), oligo(dT)1218 primers (0.5 Wg/ml), reverse transcrip-
tase bu¡er, dNTP mix (10 mM each), 25 U RNasin (RNase inhibi-
tor, Gibco-BRL), MoMLV reverse transcriptase (200 U, Gibco-
BRL) and RNase free water to 20 Wl, incubated at 70‡C for 10 min
and 37‡C for 90 min. The reaction was stopped by heating at 90‡C
for 5 min. A 1/5 volume of the generated cDNA was used for am-
pli¢cation. The PCR was performed in a total volume of 100 Wl
with 1 WM each of the sense and antisense primers, PCR bu¡er
with 2.5 mM magnesium chloride, dNTP (0.2 mM) and Taq poly-
merase (0.5 U, Roche, Mannheim, Germany)
Fig. 2. [3H]AA release by stimulated 1231N1 cells. Cells labeled
with 0.5 WCi/ml [3H]AA overnight were stimulated for 90 min (A)
or 24 h (B) with di¡erent stimuli: 40 ng/ml TNF-K, 40 ng/ml IL-1K,
200 ng/ml LPS, 50 ng/ml phorbol myristate acetate plus 1 WM
A23187 (Ca2þ ionophore), or 100 nM okadaic acid, in the presence
of 0.1 mg/ml bovine serum albumin. The supernatants were re-
moved, and assayed for radioactivity by liquid scintillation counting,
as previously described [33].
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responsive state of K2-adrenergic receptors and potentiate the
release of norepinephrine. TNF-K also increases the frequency
of spontaneous synaptic current through a presynaptic mech-
anism, augments evoked synaptic activity, and inhibits long-
term potentiation in hippocampal neurons [33]. After injury,
activated microglia are a major source of TNF-K, contribut-
ing to early neuronal damage, but improving neuronal recov-
ery at later times (2^4 weeks) [30,33]. It is now known that
TNF-K participates in apoptotic processes in the nervous sys-
tem by activating Fas receptors and signaling mechanisms
that are involved in this type of death [11]. Both IL-1 and
TNF-K have been described as modulators of PLA2 activity
and/or expression in cells from the nervous system [34].
Since astrocytes are able to respond to external injury we
studied PLA2 activation by injury/in£ammation-related fac-
tors such as IL-1K or bacterial LPS, a lipid present in gram-
positive bacteria. Experiments with [3H]AA labeled cells were
carried out, and after 1.5 h treatment a signi¢cant release of
[3H]AA was achieved by LPS as well as the control stimuli
TNF-K, phorbol myristate acetate plus A23187, and okadaic
acid (Fig. 2A). However, at 24 h, the stimulation with IL1-K
resulted in cellular responses higher than those of LPS (Fig.
2B). AA release by IL-1K has also been shown in primary
cultures of neonatal murine astrocytes [35] and in primary
cultures of ovine astroglia [36]. Our studies on the time-course
of [3H]AA release in response to LPS and IL-1K revealed that
the response to optimal LPS doses (200 ng/ml) reached a
plateau after 2 h treatment. Interestingly, AA release from
cells stimulated with 40 ng/ml IL-1K plateaued after 20 h of
incubation (data not shown). This behavior suggests the in-
triguing possibility that IL-1 needs the induction and expres-
sion of di¡erent factors to release AA from the phospholipid
stores. In this sense, it has been described that in primary
cultures of mice striatal astrocytes IL-1L treatment for 24 h
enhances ATP-evoked release of AA [37]. The molecular
mechanisms involved include both the induction of the puri-
nergic receptor P2Y2 and an increase in the amount of GIV
PLA2 protein. P2Y2 receptors appear to be absent in untreated
astrocytes but their expression is induced by IL-1 [37]. Thus
stimulation by IL-1 would induce the appearance of P2Y2
receptors in the membrane of stimulated astrocytes. Under
such conditions, ATP coming from damaged neurons in the
location of in£ammation or injury could then further activate
the astrocytes contributing to the events that end in AA re-
lease. Further experimentation is required to conclude if the
astrocytoma 1231N1 cell line has the same behavior and re-
quirements as the striatal mouse astrocytes after IL-1 stimu-
lation.
PLA2 inhibitors were used to implicate the involvement of
GIV PLA2 in the AA release. Methyl arachidonyl-£uoro-
phosphonate (MAFP) is an active-site directed, irreversible
inhibitor of GIV PLA2 and has been used to implicate GIV
PLA2 in the release of AA in many systems [5]. Di¡erent
doses of MAFP were preincubated for 30 min with cells prior
to stimulation with 200 ng/ml LPS and a profound inhibition
of the [3H]AA release with 10^50 WM MAFP treatment was
detected (Fig. 3). However, due to the fact that MAFP is not
an speci¢c inhibitor, more experimentation needs to be done
to conclude which PLA2 form is important for AA release in
this cell line.
By using organotypic cultures of rat hippocampal slices, it
has recently been shown that conditions that mimic ischemia,
like oxygen and glucose deprivation (OGD) cause an increase
in hippocampal PLA2 activity [38]. Those conditions promote
neuronal death. However, blockade of PLA2 activity during
OGD exposure improved survival of hippocampal neurons.
This e¡ect was observed only with inhibitors for GIV PLA2
like arachidonyl £uoromethyl ketone, but not with inhibi-
tors for GVI (bromoenol lactone) or for secretory PLA2
(LY311727) [38], suggesting an adverse e¡ect of GIV PLA2
on neuron survival under ischemic conditions. It is possible
that, at least in the hippocampus, these e¡ects are due to AA
metabolism by lipoxygenases, since lipoxygenase inhibitors
reduce neural injury in hippocampal rat slices [39].
Besides PLA2’s role during nervous system damage, some
evidence exists to allow speculation that PLA2 can serve a
bene¢cial role in this system. For example, it has been de-
scribed that PLA2 expression is developmentally regulated
[16], also a role for PLA2 activation in nerve regeneration
has been proposed [40], and ¢nally particularly high PLA2
activity has been found in neuronal growth cones [41]. Addi-
tionally, polyunsaturated fatty acids such AA and linoleic acid
have been shown to prevent neuronal death in rodent models
of transient global ischemia [42]. Therefore, PLA2 could have
both a protective role and a destructive activity, depending on
the local injury/in£ammation conditions.
4. COX: involvement in injury/in£ammation processes in the
nervous system
In the early 1980s it was reported that prostaglandin E2
(PGE2) is produced by mice glial cells treated with LPS [43].
The ¢rst step in PGE2 production is the oxidation of AA,
which is catalyzed by a COX. There are two COX isoenzymes,
COX-1, that generally is a constitutive form, and COX-2, an
inducible enzyme that, in some cases, is also expressed under
basal conditions. COX-2 is expressed throughout the fore-
brain in discrete populations of neurons and is enriched in
Fig. 3. Inhibition of [3H]AA release by MAFP in LPS stimulated
1231N1 cells. Labeled cells were preincubated with di¡erent concen-
trations of MAFP for 30 min, and then treated with 200 ng/ml of
LPS (¢lled circles) or media (open circles) for 2 h. Supernatants
were recovered and assayed for radioactivity by liquid scintillation
counting.
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the cortex and hippocampus in the rat nervous system [44].
No expression has been detected in glial or vascular endothe-
lial cells in normal brain [44]. However, COX-2 can be in-
duced in those cells by pro-in£ammatory/injury factors such
as IL-1 or LPS. In cultured mouse astrocytes, COX-2 expres-
sion and PGE2 production is enhanced by IL-1L after 4 h [45].
Other studies have shown that, in rat hypothalamic astro-
cytes, LPS induces PGE2 release after only 1 h of incubation,
but in this case, 80% of PGE2 production is accounted for by
COX-1 [46]. Recent work has shown that IL-1L coming from
peripheral sites of in£ammation induces COX-2 expression in
the central nervous system, and spinal cord neurons contrib-
uting to in£ammatory pain hypersensitivity developed in the
neighboring uninjured tissue [47]. Moreover, intravenous in-
jection of IL-1L enhances expression of COX-2 and PGE2
synthase (the terminal enzyme in the synthesis of PGE2) in
mouse cerebral blood vessels (mainly in endothelial cells and
perivascular macrophages) [48]. Possibly PGE2 produced in
those sites di¡uses into the brain parenchyma and acts on
PGE2 receptors to induce cellular responses [48].
The astrocytoma cell line 1231N1 expresses COX-1 and
GIV PLA2 (Fig. 4). Western-blots performed with proteins
from cells stimulated with IL-1K, LPS or TNF-K for 24 h
showed an important induction of COX-2 expression above
basal levels, without changes in the expression of COX-1 (Fig.
4). We have also studied the production of PGE2 after cell
treatment with IL-1K and LPS. Supernatants from control
and stimulated cells were assayed for PGE2 by a speci¢c ra-
dio-immunoassay. As shown in Table 2, both IL-1K and LPS
treated cells induced the synthesis of PGE2 well above the
levels found in unstimulated cells. These results point to the
possibility that AA released from phospholipids is subse-
quently metabolized to PGE2 through a COX-2 enzyme in
this cell line.
In summary, the distinct pattern of expression of PLA2
forms in the brain and their regulation by injury/in£ammatory
stimuli suggest that this family of lipases may play an impor-
tant role in brain function and pathology. In this context, the
human astrocytoma cell line 1231N1 constitutes an attractive
cell model to study, in a de¢ned cellular setting, the precise
role of the di¡erent GIV PLA2 forms in glial function and
response to damage.
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